Awake Prone Positioning for Severe Acute Chest Syndrome
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Nov 18, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called Awake Prone Positioning (APP) to see if it can help people with severe acute chest syndrome (ACS), a serious condition that affects individuals with sickle cell anemia. ACS is a leading cause of hospitalization and death in these patients. The researchers believe that by having patients lie face down while awake, it may improve their breathing and oxygen levels, making it easier for their lungs to work properly.
To be eligible for this trial, participants must be adults over 18 years old with major sickle cell anemia and currently in the intensive care unit for ACS. They will need to provide written consent and be registered in the French social insurance system. However, certain individuals won't be able to participate, such as pregnant or breastfeeding women, those who need immediate breathing assistance, or individuals with certain medical conditions. If eligible, participants can expect close monitoring and care while trying this new positioning method to potentially improve their breathing and overall condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years
- • Major sickle cell anemia (SS, SC, Sβ)
- • Admission in intensive care unit for ACS
- • Registered in the French social insurance regime.
- • Written, informed consent
- Exclusion Criteria:
- • Pregnant or breastfeeding women
- • Immediate need for intubation
- • Impaired vigilance status (Glasgow scale score \< 12)
- • Pneumothorax
- • Haemodynamically unstable
- • Thoracic trauma admission
- • Severely obese with body-mass index higher than 40 kg/m²
- • EIT contraindication: pacemaker, automatic implantable defibrillators, skin lesions facing the EIT belt, unstable rachis fracture or medullary lesions
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Matthieu Turpin, MD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Muriel Fartoukh, MD, PhD
Study Chair
Assistance Publique - Hôpitaux de Paris
Alexandre Elabbadi, MD
Study Chair
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported